New computational method integrates multiple molecular data types to study the variability between patients in complex diseases
To understand the biology of diseased organs researchers can use different types of molecular data
One of the biggest computational challenges at the moment is integrating the resulting multiple data types
A new computational method jointly analyses different types of molecular data and disentangles the sources of disease variability to guide personalised treatment
EMBL researchers have designed a computational method to jointly analyse multiple types of molecular data from patients in order to identify molecular signatures that distinguish individuals. The method is called Multi-Omics Factor Analysis (MOFA), and was published in Molecular Systems Biology. MOFA could be particularly useful for understanding cancer development, improving diagnosis and suggesting new directions for personalised treatment.
The researchers tested their new method on multi-omics data collected from 200 leukaemia patients. MOFA identified a series of factors that highlighted the molecular variability between patients. This information could help researchers understand how cancer develops at an individual level. It could also help steer personalised treatment decisions.
What is multiomics data?
Multi-omics approaches integrate data from the genome, epigenome, transcriptome, metabolome, and other molecular data. These data types have different properties and dimensions and are difficult to integrate into a comprehensive analysis to build an individual’s molecular profile.
However, by combining multiple molecular data types (multi-omics), researchers can identify biomarkers – naturally occurring molecules, genes or molecular characteristics associated with a particular disease. Biomarkers are essential for clinical research and to stratify patients. By measuring biomarkers, we can understand a patient’s disease better and estimate what kind of treatment they will respond to best.
“The big challenge in cancer is that each patient’s disease is different from a molecular point of view and has a unique set of molecular features that have led to its development,” explains Ricard Argelaguet, Predoctoral Fellow in the Stegle group, at the European Bioinformatics Institute (EMBL-EBI). “Our method allows researchers to do something that couldn’t be done before – to easily integrate complex molecular data from DNA, RNA, methylation and more to build a tumour’s molecular profile. Using these profiles, the method can also stratify patients into groups that may benefit from different types of treatment.”
“Our objective was to come up with a method that could easily be used by clinical researchers, so we worked with colleagues from the field to understand their needs and challenges,” continues Britta Velten, Predoctoral Fellow in the Huber group at EMBL Heidelberg. “We combined expertise from maths, statistics, machine learning, biology and clinical medicine to come up with a robust and practicalmethod, which will hopefully help researchers in a clinical setting to improve cancer diagnosis and treatment.”
In a second application, the researchers also used MOFA to analyse multi-omics data at single-cell resolution. They are currently working to further improve the method so that it can cope with even larger data sets and additional experimental designs.
MOFA is available as open source software at https://github.com/bioFAM/MOFA with extensive documentation and tutorials.
ARGELAGUET, R*, VELTEN B*, et al. (2018). Multi-omics Factor Analysis—a framework for unsupervised integration of multi-omics data sets. Molecular Systems Biology. Published online 19 June 2018. DOI:
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 635290.
This post was originally published on EMBL news.
Engagement Team Lead, Meyerhofstraße 1, 69117 Heidelberg, Germany
|Tel:||+49 6221 387-8443|
EMBL Press Officer, Meyerhofstraße 1, 69117 Heidelberg, Germany
|Tel:||+49 6221 387-8726|
Policy regarding use
Press and Picture Releases
EMBL press and picture releases including photographs, graphics, movies and videos are copyrighted by EMBL. They may be freely reprinted and distributed for non-commercial use via print, broadcast and electronic media, provided that proper attribution to authors, photographers and designers is made.